Paying attention to clinical endpoint events of viral hepatitis and efficacy evaluationZHANG Chong, DOU Xiao-guang353-354
Virological response and clinical endpoint events in patients with chronic hepatitis BLI Lan-qing, ZHOU Jing, CHEN En-qiang355-359
Effect of different antiviral drugs on clinical outcomes of liver cirrhosis due to hepatitis BWANG Zhe, HU Ke, YU Yan-yan, XU Xiao-yuan, XU Jing-hang360-363
Clinical outcomes after DAAs treatment for patients with hepatitis C cirrhosisZOU Ming-nan, CAI Da-chuan364-368,374
Antiviral efficacy evaluation indicators for patients with chronic hepatitis B and chronic hepatitis CYU Ning, FAN Rong369-374
Research status and countermeasures of chronic liver disease complicated with hepatitis E virus infectionHE Ying-li375-377
Clinical outcome of viral hepatitis E in the elderly patients and the prevention strategiesZHANG Xiang-tong, DING Yang378-380
Review of important clinical advances related to diabetes in 2022HU Yu-chen, ZHENG Yi-ran, DU Tao, ZHANG Yu-wei381-383,389
Study on the prevalence of frailty and influencing factors in hospitalized elderly patients with type 2 diabetes mellitusZHANG Ning, LIU Xiao-hong, ZHU Ming-lei, QU Xuan, GE Nan, WANG Qiu-mei384-389
Prediction model for inflammation degree in chronic hepatitis B patients:a retrospective studyWANG Juan-xia, CHEN Xin-yue, WEI Shi-bo, SUN Xin-ce, ZHU Hao-yu, LIANTANG You-you, DU Yu-feng390-395